4142 Stock Overview
Adimmune Corporation manufactures and sells human vaccines in Taiwan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4142 from our risk checks.
Adimmune Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$26.50 |
52 Week High | NT$41.25 |
52 Week Low | NT$26.20 |
Beta | 0.46 |
1 Month Change | -10.62% |
3 Month Change | -20.06% |
1 Year Change | -32.83% |
3 Year Change | -53.91% |
5 Year Change | 29.90% |
Change since IPO | -62.14% |
Recent News & Updates
Shareholder Returns
4142 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -0.2% | 1.2% | -0.3% |
1Y | -32.8% | -20.4% | 25.8% |
Return vs Industry: 4142 underperformed the TW Biotechs industry which returned -21.1% over the past year.
Return vs Market: 4142 underperformed the TW Market which returned 26.7% over the past year.
Price Volatility
4142 volatility | |
---|---|
4142 Average Weekly Movement | 2.2% |
Biotechs Industry Average Movement | 4.3% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.1% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 4142's share price has been volatile over the past 3 months.
Volatility Over Time: 4142's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1965 | 564 | Steve Chan | https://www.adimmune.com.tw |
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.
Adimmune Corporation Fundamentals Summary
4142 fundamental statistics | |
---|---|
Market cap | NT$11.17b |
Earnings (TTM) | -NT$165.25m |
Revenue (TTM) | NT$1.81b |
6.2x
P/S Ratio-67.6x
P/E RatioIs 4142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4142 income statement (TTM) | |
---|---|
Revenue | NT$1.81b |
Cost of Revenue | NT$1.24b |
Gross Profit | NT$568.97m |
Other Expenses | NT$734.22m |
Earnings | -NT$165.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.39 |
Gross Margin | 31.43% |
Net Profit Margin | -9.13% |
Debt/Equity Ratio | 42.7% |
How did 4142 perform over the long term?
See historical performance and comparison